Skip to main content

Table 1 Characteristics of patients with spondylarthritis and rheumatoid arthritis in BIOBADASER and medications used by diagnosis

From: Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER

      Total treatments with biologics, n (percentage) by diagnosis
  n (percentage) by diagnosis in BIOBADASER Age* n (percentage), women Disease duration* Infliximab Etanercept Adalimumab
Rheumatoid arthritis 4,006 (68.5) 54 ± 13 3,166 (79.0) 10 ± 7 2,789 (60.6) 1,170 (25.4) 577 (12.5)
All spondylarthritis 1,524 (26.0) 45 ± 12 537 (35.2) 10 ± 8 1,180 (70.7) 472 (28.3) 15 (0.9)
   Ankylosing spondylitis 657 (11.2) 45 ± 12 152 (23.1) 12 ± 8 570 (80.5) 136 (19.2) 2 (0.3)
   Psoriatic arthritis 570 (9.7) 47 ± 12 270 (47.4) 9 ± 7 347 (54.5) 281 (44.1) 9 (1.4)
   Undifferentiated spondylarthritis 187 (3.2) 43 ± 12 70 (37.4) 8 ± 7 162 (79.0) 41 (20.0) 2 (1.0)
   Crohn's disease arthritis 68 (1.2) 38 ± 13 32 (47.1) 7 ± 8 68 (94.4) 2 (2.8) 1 (1.4)
   Juvenile spondylarthritis 19 (0.3) 30 ± 12 7 (36.8) 17 ± 14 17 (89.5) 2 (10.5) -
   Reactive arthritis 12 (0.2) 49 ± 9 2 (16.7) 8 ± 7 10 (83.3) 2 (16.7) -
   Chronic seronegative oligoarthritis 11 (0.2) 35 ± 9 4 (36.4) 4 ± 3 6 (40.0) 8 (53.3) 1 (6.7)
  1. *In years, mean ± standard deviation
  2. p < 0.001 of the difference between rheumatoid arthritis and spondylarthritis as a group.